Status:
COMPLETED
A Study to Evaluate the Effect of Nasal Insulin on Postprandial Glycemic Control in Type 2 Diabetic Patients
Lead Sponsor:
Nastech Pharmaceutical Company, Inc.
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Insulin is a hormone which is produced by the human pancreas for the lowering of blood sugar. In patients who don't produce enough insulin, additional insulin must be given several times per day by in...
Detailed Description
This study is being conducted to evaluate the effect on postprandial glucose levels and safety of Nastech's insulin nasal spray compared with a rapid acting insulin (i.e., insulin aspart) in Type 2 di...
Eligibility Criteria
Inclusion
- Type 2 diabetes for at least 3 months
- Type 2 diabetics on oral antidiabetic medicines and/or insulin therapies
Exclusion
- Patients taking intermediate acting insulin such as NPH
- Recurrent severe hypoglycemia
- Patients with late diabetic complications
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00624767
Start Date
March 1 2008
End Date
May 1 2008
Last Update
May 20 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Diabetes and Glandular Disease Research Associates
San Antonio, Texas, United States, 78258